SCHEMBL4242223

SCHEMBL4242223

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Oc4ccc(NC(=O)NC(CC)CC)cc4COC)c(C)c3)cc2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MCHR1 Q99705 2/20 0.37
HTR4 Q13639 1/20 0.36
LMNA P02545 2/20 0.36
OPRM1 P35372 2/20 0.36
OPRD1 P41143 2/20 0.36
HRH3 Q9Y5N1 2/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
PKM P14618 1/20 0.36
CCR3 P51677 1/20 0.36
PGR P06401 1/20 0.35
AR P10275 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HTR1D P28221 2/20 0.35
SLC6A5 Q9Y345 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236550 0.94 MCHR1 (0.40) MEN1KMT2ASMN1; SMN2NPSR1MCHR1
SCHEMBL4683606 0.94 HRH3 (0.42) MCHR1HRH3PKMPGRAR
SCHEMBL4240249 0.91 SMN1; SMN2 (0.45) MEN1KMT2ASMN1; SMN2NPSR1MCHR1
SCHEMBL4236318 0.91 MCHR1 (0.39) MEN1KMT2ASMN1; SMN2NPSR1MCHR1
SCHEMBL4233740 0.91 MCHR1 (0.39) MEN1KMT2ASMN1; SMN2NPSR1MCHR1
SCHEMBL4690069 0.90 SMN1; SMN2 (0.41) SMN1; SMN2NPSR1MCHR1LMNAHRH3
SCHEMBL4686839 0.89 CCR3 (0.46) MEN1KMT2AHTR4LMNAOPRM1
SCHEMBL4232082 0.89 HRH3 (0.45) HRH3
SCHEMBL4238977 0.88 MCHR1 (0.39) MEN1KMT2ASMN1; SMN2NPSR1MCHR1
SCHEMBL4886073 0.88 MEN1 (0.35) MEN1KMT2ASMN1; SMN2NPSR1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R MEN1 2447/4885KMT2A 3436/4885SMN1; SMN2 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.